.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG12_Ofatumumab.Ofatumumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG12_Ofatumumab.Ofatumumab| name: | Ofatumumab |
| ATC code: | L04AG12 | route: | subcutaneous |
| n-compartments | 2 |
Ofatumumab is a fully human monoclonal antibody that specifically binds to the CD20 molecule present on the surface of B lymphocytes. It is used primarily for the treatment of chronic lymphocytic leukemia (CLL) and relapsing forms of multiple sclerosis (MS). Ofatumumab is approved and currently in clinical use for these indications.
Pharmacokinetic parameters are reported in adult patients with relapsing multiple sclerosis receiving subcutaneous ofatumumab.
Yu, H, et al., & Soelberg Sørensen, P (2022). Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS drugs 36(3) 283–300. DOI:10.1007/s40263-021-00895-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/35233753